Applications of Proteomics in Ovarian Cancer: Dawn of a New Era
The ability to identify ovarian cancer (OC) at its earliest stages remains a challenge. The patients present an advanced stage at diagnosis. This heterogeneous disease has distinguishable etiology and molecular biology. Next-generation sequencing changed clinical diagnostic testing, allowing assessm...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Proteomes |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-7382/10/2/16 |
| _version_ | 1797482851687464960 |
|---|---|
| author | Aruni Ghose Sri Vidya Niharika Gullapalli Naila Chohan Anita Bolina Michele Moschetta Elie Rassy Stergios Boussios |
| author_facet | Aruni Ghose Sri Vidya Niharika Gullapalli Naila Chohan Anita Bolina Michele Moschetta Elie Rassy Stergios Boussios |
| author_sort | Aruni Ghose |
| collection | DOAJ |
| description | The ability to identify ovarian cancer (OC) at its earliest stages remains a challenge. The patients present an advanced stage at diagnosis. This heterogeneous disease has distinguishable etiology and molecular biology. Next-generation sequencing changed clinical diagnostic testing, allowing assessment of multiple genes, simultaneously, in a faster and cheaper manner than sequential single gene analysis. Technologies of proteomics, such as mass spectrometry (MS) and protein array analysis, have advanced the dissection of the underlying molecular signaling events and the proteomic characterization of OC. Proteomics analysis of OC, as well as their adaptive responses to therapy, can uncover new therapeutic choices, which can reduce the emergence of drug resistance and potentially improve patient outcomes. There is an urgent need to better understand how the genomic and epigenomic heterogeneity intrinsic to OC is reflected at the protein level, and how this information could potentially lead to prolonged survival. |
| first_indexed | 2024-03-09T22:39:25Z |
| format | Article |
| id | doaj.art-22babc0c1c684a5da9c4a680fd9e0dd6 |
| institution | Directory Open Access Journal |
| issn | 2227-7382 |
| language | English |
| last_indexed | 2024-03-09T22:39:25Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Proteomes |
| spelling | doaj.art-22babc0c1c684a5da9c4a680fd9e0dd62023-11-23T18:42:47ZengMDPI AGProteomes2227-73822022-05-011021610.3390/proteomes10020016Applications of Proteomics in Ovarian Cancer: Dawn of a New EraAruni Ghose0Sri Vidya Niharika Gullapalli1Naila Chohan2Anita Bolina3Michele Moschetta4Elie Rassy5Stergios Boussios6Department of Medical Oncology, Barts Cancer Centre, St. Bartholomew’s Hospital, Barts Health NHS Trust, London EC1A 7BE, UKSchool of Biosciences Education, Faculty of Life Sciences and Medicine, King’s College London, London WC2R 2LS, UKDepartment of Medical Oncology, Barts Cancer Centre, St. Bartholomew’s Hospital, Barts Health NHS Trust, London EC1A 7BE, UKDepartment of Haematology, Clatterbridge Cancer Centre Liverpool, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool L7 8YA, UKNovartis Institutes for BioMedical Research, 4033 Basel, SwitzerlandDepartment of Medical Oncology, Gustave Roussy Institut, 94805 Villejuif, FranceDepartment of Medical Oncology, Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, UKThe ability to identify ovarian cancer (OC) at its earliest stages remains a challenge. The patients present an advanced stage at diagnosis. This heterogeneous disease has distinguishable etiology and molecular biology. Next-generation sequencing changed clinical diagnostic testing, allowing assessment of multiple genes, simultaneously, in a faster and cheaper manner than sequential single gene analysis. Technologies of proteomics, such as mass spectrometry (MS) and protein array analysis, have advanced the dissection of the underlying molecular signaling events and the proteomic characterization of OC. Proteomics analysis of OC, as well as their adaptive responses to therapy, can uncover new therapeutic choices, which can reduce the emergence of drug resistance and potentially improve patient outcomes. There is an urgent need to better understand how the genomic and epigenomic heterogeneity intrinsic to OC is reflected at the protein level, and how this information could potentially lead to prolonged survival.https://www.mdpi.com/2227-7382/10/2/16ovarian cancersignaling pathwaysproteomic biomarkersproteomic techniquesmultiomicspeptidomics |
| spellingShingle | Aruni Ghose Sri Vidya Niharika Gullapalli Naila Chohan Anita Bolina Michele Moschetta Elie Rassy Stergios Boussios Applications of Proteomics in Ovarian Cancer: Dawn of a New Era Proteomes ovarian cancer signaling pathways proteomic biomarkers proteomic techniques multiomics peptidomics |
| title | Applications of Proteomics in Ovarian Cancer: Dawn of a New Era |
| title_full | Applications of Proteomics in Ovarian Cancer: Dawn of a New Era |
| title_fullStr | Applications of Proteomics in Ovarian Cancer: Dawn of a New Era |
| title_full_unstemmed | Applications of Proteomics in Ovarian Cancer: Dawn of a New Era |
| title_short | Applications of Proteomics in Ovarian Cancer: Dawn of a New Era |
| title_sort | applications of proteomics in ovarian cancer dawn of a new era |
| topic | ovarian cancer signaling pathways proteomic biomarkers proteomic techniques multiomics peptidomics |
| url | https://www.mdpi.com/2227-7382/10/2/16 |
| work_keys_str_mv | AT arunighose applicationsofproteomicsinovariancancerdawnofanewera AT srividyaniharikagullapalli applicationsofproteomicsinovariancancerdawnofanewera AT nailachohan applicationsofproteomicsinovariancancerdawnofanewera AT anitabolina applicationsofproteomicsinovariancancerdawnofanewera AT michelemoschetta applicationsofproteomicsinovariancancerdawnofanewera AT elierassy applicationsofproteomicsinovariancancerdawnofanewera AT stergiosboussios applicationsofproteomicsinovariancancerdawnofanewera |